A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of FWD1509 MsOH in Advanced Non-Small Cell Lung Cancer
This study is testing a new experimental medicine called FWD1509 MsOH to see how it works against advanced non-small cell lung cancer. The researchers want to figure out the safest and most effective dose for patients to take.
This study is for adults with advanced lung cancer that has spread and cannot be cured by standard treatments. You must have specific genetic markers in your tumor, like an EGFR or HER2 mutation, to be eligible.
Participants will receive the experimental medicine while the research team closely monitors their health and safety. You will need to provide tumor tissue samples so doctors can study how your cancer responds to the treatment.
The study is currently taking place in Canton, Ohio, and Houston, Texas. The study status is listed as unknown, so we recommend contacting the trial site directly for the most current information.
- 1Researchers are testing a new treatment for advanced lung cancer.
- 2Participation requires having specific genetic mutations in your tumor.
- 3The primary goal is to determine the best and safest dose of the new medication.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.